21 October 2022 | Other

Immune response from Moderna's updated Omicron vaccine persists for 3 months

Moderna Inc's COVID-19 booster vaccine, aimed at the BA.1 Omicron strain, elicits a powerful immune reaction against this subvariant, keeping antibodies at a high level for at least three months, as reported by the company.

The vaccine developed by Moderna against the Omicron variant has already received regulatory approval in a number of countries.

Stephane Bancel, Chief Executive Officer of Moderna Inc, said that clinical trials have shown an excellent immune response, which has been achieved with the help of a bivalent booster and retains its effect for at least 3 months.

The company also noted that the data regarding the trials of its target vaccine BA.4/BA.5 in humans are expected later this year.

Company MarketCheese
Period: 25.06.2026 Expectation: 235 pips
ETHUSD sell-off targets $1,500
Today at 09:12 AM 3
Gold sell
Period: 25.06.2026 Expectation: 2100 pips
Sell gold with $4,110 in sight as Fed stays hawkish
Today at 06:40 AM 19
Period: 30.06.2026 Expectation: 400 pips
Покупка USDJPY до уровня 160,00
Today at 05:26 AM 30
Period: 31.12.2026 Expectation: 1800 pips
Invest in SPX with $7,700 in view
Today at 04:47 AM 9
Period: 30.06.2026 Expectation: 1500 pips
Buying Brent crude from $72.5 per barrel
Today at 04:47 AM 12
Period: 24.06.2026 Expectation: 720 pips
USDCAD shows signs of continued rally after exiting overbought territory
Yesterday at 12:00 PM 25
Go to forecasts